Dai Xiaomeng, Xue Jun, Hu Jianli, Yang Sheng-Li, Chen George G, Lai Paul B S, Yu Chao, Zeng Cui, Fang Xiefan, Pan Xiaoli, Zhang Tao
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Transl Oncol. 2017 Aug;10(4):511-517. doi: 10.1016/j.tranon.2017.03.009. Epub 2017 May 27.
Recurrence or metastasis of hepatocellular carcinoma (HCC) is mainly intrahepatic after curative resection, demonstrating that the peritumoral environment is important but often neglected. Programmed death ligand 1 (PD-L1) in intratumoral liver tissues is a poor prognosis factor whose impact is removed after curative resection. However, PD-L1 expression remains in the peritumoral liver tissues and its distribution and prognostic value are still not clear.
We assessed the expression of PD-L1 by immunohistochemistry in peritumoral liver tissues from 90 HCC patients who underwent curative hepatectomy. The results were validated in an independent cohort of additional 90 HCC patients.
We found PD-L1 positive expression in 31.11% (28/90) of peritumoral tissues. Peritumoral PD-L1 expression was associated with a significantly worse overall survival (OS) (P=.000) and disease-free survival (DFS) (P=.001) compared to the negative expression group. Additionally, peritumoral PD-L1 positivity significantly correlated with vascular invasion and a lower albumin level (≤35 g/L). Univariate and multivariate Cox regression models both revealed peritumoral PD-L1 as an independent prognostic factor for OS (HR=2.853, P=.002) and DFS (HR=2.362, P=.003). The prognostic value of PD-L1 positivity was validated in the independent data set.
Our data suggest PD-L1 expression in peritumoral hepatocytes is an independent prognostic factor for OS and DFS. This implies that future anti-cancer therapy should target not only residual tumor cells but also the "soil" for promoting tumor growth. Peritumoral PD-L1 could be a good target for adjuvant therapy after hepatectomy.
肝细胞癌(HCC)根治性切除术后复发或转移主要发生在肝内,这表明瘤周环境很重要,但常被忽视。肿瘤内肝组织中的程序性死亡配体1(PD-L1)是一个预后不良因素,其影响在根治性切除后消除。然而,PD-L1表达仍存在于瘤周肝组织中,其分布及预后价值尚不清楚。
我们通过免疫组织化学评估了90例行根治性肝切除术的HCC患者瘤周肝组织中PD-L1的表达。结果在另外90例HCC患者的独立队列中得到验证。
我们发现31.11%(28/90)的瘤周组织中存在PD-L1阳性表达。与阴性表达组相比,瘤周PD-L1表达与总生存期(OS)显著较差(P = 0.000)和无病生存期(DFS)显著较差(P = 0.001)相关。此外,瘤周PD-L1阳性与血管侵犯及较低的白蛋白水平(≤35 g/L)显著相关。单因素和多因素Cox回归模型均显示瘤周PD-L1是OS(HR = 2.853,P = 0.002)和DFS(HR = 2.362,P = 0.003)的独立预后因素。PD-L1阳性的预后价值在独立数据集中得到验证。
我们的数据表明瘤周肝细胞中PD-L1表达是OS和DFS的独立预后因素。这意味着未来的抗癌治疗不仅应针对残留肿瘤细胞,还应针对促进肿瘤生长的“土壤”。瘤周PD-L1可能是肝切除术后辅助治疗的良好靶点。